You are here

  • Home
  • Archive
  • Volume 25, Issue Suppl 1
  • 1ISG-005 A cost-effectiveness analysis of nivolumab versus docetaxel for advanced nonsquamous non-small-cell lung cancer in second line in a healthcare setting

Article info

Article menu
Download PDFPDF
Section 1: Introductory statements and governance
1ISG-005 A cost-effectiveness analysis of nivolumab versus docetaxel for advanced nonsquamous non-small-cell lung cancer in second line in a healthcare setting

Authors

Citation

Román AF, Lázaro CB, Fernández JL, et al
1ISG-005 A cost-effectiveness analysis of nivolumab versus docetaxel for advanced nonsquamous non-small-cell lung cancer in second line in a healthcare setting
European Journal of Hospital Pharmacy 2018;25:A2-A3.

Publication history

  • First published March 2, 2018.
Online issue publication 
April 21, 2018

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions